Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers

Therapeutic Drug Monitoring

Volumn 21, Issue 3, 1999, Pages 304-309

  Penzak, Scott R ^a   Gubbins, Paul O ^b   Gurley, Bill J ^c   Wang, Pei Ling ^c   Saccente, Michael ^b  

^a MERCER UNIVERSITY   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Absorption; CYP3A4; Grapefruit juice; Itraconazole

Indexed keywords

ITRACONAZOLE; SPORONOX; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG FORMULATION; DRUG METABOLISM; DRUG SOLUBILITY; FEMALE; FOOD DRUG INTERACTION; FRUIT JUICE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH EMPTYING; STOMACH PH;

ADULT; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; CAPSULES; CITRUS; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; ITRACONAZOLE; MALE; MIXED FUNCTION OXYGENASES; REFERENCE VALUES;

EID: 0033045768     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199906000-00009     Document Type: Article

References (33)

1. Cauwenbergh G, De Doncker P, Stoops K, De Dier AM. Goyvaerts H, Schuermans V. Itraconazole in the treatment of human mycoses: review of three years of clinical experience. Rev Infect Dis 1987:9(suppl 1):146-52
2. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994;330:263-72.
3. Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989:32(suppl 1):67-87.
4. Grant SM, Clissold SP. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989;37:310-44.
5. Smith D, Van De Velde V, Woestenboghs R, Gazzard BG. The pharmacokinetics of oral itraconazole in AIDS patients. J Pharm Pharmacol 1992;44:618-9.
6. 2 blockers. J Clin Pharmacol 1997;37:535-40.
7. Jaruratanasirikul S, Kleepkaew A. Influence of an acidic beverage (Coca-cola) on the absorption of itraconazole. Eur J Clin Pharmacol 1997;52:235-7.
8. Data on File, Janssen Pharmaceutica. B-2340 Beerse, Belgium.
9. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A4 protein expression. J Clin Invest 1997;99:2545-53.
10. Rashid TJ, Martin U, Clarke H, Waller DG, Renwick AG. George CF. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 1995;40:51-8.
11. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995;57:485-91.
12. Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krähenbühl S. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995;58:20-8.
13. Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 1995;58:127-31.
14. He K, Iyer KR, Haves RN, Sinz MW, Woolf TF, Hollenberg PF. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 1998;11:252-9.
15. Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet 1997;33:103-21.
16. Edwards DJ, Bellevue FH, Woster PM. Identification of 6′,7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 1996;24:1287-90.
17. Tricot G, Joosten E, Boogaerts MA, Vande Pitte J, Cauwenbergh G. Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Rev Infect Dis 1987:9(suppl 1):94-9.
18. Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, DeBeule K. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989;32 (suppl 1): 103-8.
19. Gubbins PO, Gurley BJ, Bowman J. Rapid and sensitive high performance liquid Chromatographic method for the determination of itraconazole and its hydroxy-metabolite in human serum. J Pharm Biomed Anal 1998;16:1005-12.
20. Gibaldi M. Compartmental and noncompartmental pharmacokinetics. In: Gibaldi M, ed. Biopharmaceutics and Clinical Pharmacokinetics, 4th ed. Philadelphia: Lea and Febiger: 1991:14-23.
21. Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993:778-84.
22. Lim SG. Sawyerr AM. Hudson M. Sercombe J. Pounder RE. The absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther 1993;7:317-21.
23. Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H. Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects. Int J Clin Pharmacol Ther 1998;36: 306-8.
24. Cheng KL, Nafziger AN, Peloquin CA. Amsden GW. Effect of grapefruit juice on clarithromycin pharmacokinetics. Antimicrob Agents Chemother 1998;42:927-9.
25. Indinavir package insert. West Point, PA: Merck &Co.: March 1996.
26. Chen C, Chin JE, Ueda K. et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (p-glycoprotein) gene from multidrug-resistant human cells. Cell 1986;47:381-9.
27. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995;13:129-34.
28. Phang JM, Poore M, Lopaczynska J, Yeh GC. Flavonol-stimulated efflux of 7,12-dimethylbenz (a) anthracene in multidrug-resistant breast cancer cells. Cancer Res 1993;53:5977-81.
29. Lown KS, Mayo RR, Leichtman AM, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62:248-60.
30. Miyama T, Takanaga H, Matsuo H, et al. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrob Agents Chemother 1998;42:1738-44.
31. Moukarzel AA, Sabri MT. Gastric physiology and function: effects of fruit juices. J Amer Coll Nutr 1996:15(suppl 5): 18-25.
32. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents: decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997;25:1228-33.
33. Abernethy DR. Grapefruits and Drugs: When is statistically significant clinically significant? J din Invest 1997:99:2297-8.